Background: Bone mineral density (BMD) loss is poorly defined in lymphoma patients. The aim of this study was to measure the extent of BMD loss in newly diagnosed lymphoma patients receiving chemotherapy.
introduction
Progress in the treatment of lymphoma has led to a dramatic improvement of survival and cure rate [1] . Consequently, the focus is shifting toward improving the quality of life of patients with these diseases. Many cancer treatments cause loss of bone mass, which may be worsened by the harmful effects of the tumor itself or its treatment on bone metabolism [2] . Women with breast cancer and men with prostate cancer have an increased risk of osteoporosis and fractures, due to chemotherapy-and hormonal-therapy-induced hypogonadism [3] . Many studies have been published concerning bone mass loss and bone metabolism in children with lymphoma and adult survivors of childhood lymphoma. In contrast, very few studies and only rare case reports of bone complications have been published in the setting of adult lymphoma patients [4, 5] .
The effects of chemotherapy and the role of the tumor itself on bone loss in adult lymphoma patients are poorly defined at the present time. High-dose intermittent corticosteroids and alkylating agents such as cyclophosphamide, which often cause gonadal dysfunction, could be major causes of bone loss, resulting in osteoporosis [6] [7] [8] . However, no robust studies using modern chemotherapy regimens have been carried out. Moreover, in clinical practice, chemotherapy is usually administered as combinations of several agents with or without radiotherapy and autologous stem cell transplantation. It is therefore difficult to identify the individual effects of each treatment and the intrinsic effect of the lymphoma on bone loss. Due to the lack of sufficient data concerning bone complications during the course of the disease, no guidelines are therefore available on whether bone investigations should be carried out in adult lymphoma patients and on which patients. The aim of this study was therefore to assess for the first time in a prospective study the extent of bone complications early in the course of the disease in adult patients with lymphoma.
patients and methods

study design
This prospective, single-center study was carried out on the departments of Hematology and Rheumatology, Amiens University Hospital, France. Consecutive patients attending lymphoma clinics who were eligible were invited to participate in the study. The study was conducted according to the provisions and amendments of the Declaration of Helsinki, International Conference on Harmonisation Guidelines for Good Clinical Practice, and national laws and procedures pertaining to clinical studies. Approval was obtained from the University Hospital of Amiens Nord-Ouest II Ethics Committee. All patients gave their written informed consent. This study is registered at www.clinicaltrials.gov as NCT 01841814.
study population
Inclusion criteria were: adult patients ≥18 years old, newly diagnosed with lymphoma and previously untreated were eligible. All patients had to be treated with chemotherapy either alone or followed by radiotherapy. Exclusion criteria were patients with known metabolic bone disease as osteoporosis and/or history of osteoporotic fractures, patients with a history of long-term corticosteroid therapy, previous radiotherapy to the lumbar spine or hip, or bone involvement by lymphoma of the lumbar spine or hip.
study assessments
The medical charts of all patients were reviewed during follow-up by a physician and demographic and clinical characteristics and risk factors for osteoporosis were also collected. Body mass index (BMI) was calculated and dietary intake of calcium was evaluated by a questionnaire. Lymphoma subtypes was classified according to the 2008 WHO Classification. The International Prognostic Index (IPI) was calculated as previously described [9, 10] . Performance status was evaluated by the Eastern Cooperative Oncology Group (ECOG) score, extra-nodal involvement was assessed by CT scan, PET scan and bone marrow biopsy. All patients had received chemotherapy according to the local guidelines for Hodgkin's and nonHodgkin's lymphoma. The cumulative dose of corticosteroids used over the year was calculated and radiotherapy and bone marrow transplant as adjuvant to chemotherapy were recorded.
biochemical parameters
All subjects underwent morning blood draws at baseline and 1 year later. Blood was collected for assessment of hemoglobin, serum albumin, serum creatinine, calcium, phosphate, alkaline phosphatase (AP), 25-hydroxyvitamin D, lactate dehydrogenase (LDH), ferritin, β2-microglobulin and C-reactive protein (CRP). Corrected calcium levels were calculated for each subject. Estimated glomerular filtration rate (GFR) was calculated using the modification of diet in renal disease (MDRD) formula (ml/min). Serum concentrations of total testosterone, free testosterone, follicle-stimulating hormone (FSH) and luteinizing hormone (LH) were determined for men before treatment and 1 year later. Serum levels of C-telopeptide (sCTX) using Cross-laps® ELISA (Immunodiagnostic Systems, France), bone-specific AP (BAP) using BAP Elisa Immunoassay Kit (MicroVue Bone Health QUIDEL, San Diego) were routinely measured on an automated immune-assay analyzer (Diasorin ETI Max 3000).
bone mineral density measurement by DXA Bone mineral density (BMD) was measured at the lumbar spine (L1-L4) and at the non-dominant hip for femoral neck and total hip by dual energy X-ray absorptiometry (QDR machines, Hologic Inc., Discovery W, Waltham, MA, in 28 patients; or DPX densitometers, GE Lunar, Prodigy, Madison, WI, in 13 patients). Machines were calibrated daily and qualityassurance tests were carried out daily and weekly. The same machine was used to measure bone density at baseline and at follow-up visits, and crosscalibrations were carried out to allow comparison of the time-course of BMD [11, 12] . WHO criteria were used in post-menopausal women to define osteoporosis (T-score less than or equal to −2.5) and osteopenia (T-score between −1.0 and −2.5). These criteria were also used for men ≥50 years old, while the Z-score was used instead of T-score for pre-menopausal women and men <50 years old.
fracture assessment
Chest, abdomen and pelvis CT with sagittal image reconstruction at baseline and 1 year later was used to evaluate the prevalence and incidence of osteoporotic vertebral fractures. Fractures were identified by one radiologist by quantitative morphometry, and defined as a 15% reduction in the height of a previously intact vertebra [13] . Non-vertebral fractures were diagnosed by patient report and were confirmed by radiography or CT ( particularly for rib fractures).
statistical analysis
Statistical analysis was carried out using SAS software, version 8.2. Descriptive statistics for quantitative parameters were expressed as mean, standard deviation; minimum, maximum, median and missing values and qualitative parameters were expressed as frequency and percentage. Statistical tests were two-sided with a significance level of 5%, based on analysis of the nature and distribution of variables (Student's t test, paired t-test, Wilcoxon signed-rank test). Logistic regression was carried out on baseline parameters possibly associated with BMD loss. Explanatory data were selected on univariate analyses according to their discriminate power (P < 0.2). Spearman's correlation coefficients were then calculated between BMD loss and baseline quantitative parameters. results baseline characteristics and at 1 year later Forty-one consenting patients (31 men) with newly diagnosed lymphoma were included. The median age of the patients at diagnosis was 59 (range: 19-86) years. Lymphoma subtypes according to the WHO classification are presented in Table 1 .
Fifty-three percent of patients had stage III-IV disease with a performance status of 0-2 in 95% of cases and extra-nodal disease was present in 44% of cases. The International Prognostic Index (IPI) for DLBCL was high in 10 (38%) patients. All patients received chemotherapy and 22% of patients received second-line treatment due to relapse or progressive (Table 1) . Three patients were treated with bisphosphonates at the beginning of the study due to baseline Z/T score less than or equal to −2.5 and/or osteoporotic fracture and six patients died before 1 year and were excluded from the analysis at 1 year. Baseline clinical, biochemical and anthropomorphic characteristics of the remaining 32 patients were compared with the nine patients excluded. The remaining 32 patients were younger (P = 0.003), had higher albumin (P = 0.002), lower corrected calcium (P = 0.01) and lower β2-microglobulin (P = 0.01). Demographic, clinical and biochemical characteristics of the remaining 32 patients at baseline and 1 year later are shown in Table 2 .
clinical characteristics. At baseline, four women were postmenopausal and three were pre-menopausal. Ovarian failure did not occur, as all three premenopausal women retained menstrual function. One patient included in the study was treated for prostate cancer by hormonal therapy, but no other cause of secondary osteoporosis was found. At baseline, none of the patients drank 3 or more units of alcohol per day, three patients presented a BMI ≤ 19 kg/m 2 and 12 patients were current smokers.
Corticosteroids were mostly administered during the first 6 months with a mean cumulative dose of 3216 ± 1963 mg. Extra-nodal involvement was demonstrated in 13 patients (bone marrow biopsy was positive in only 1 case). The mean duration of chemotherapy was 5.0 ± 2.7 months. Radiotherapy associated with chemotherapy was necessary for eight patients and autologous stem cell transplants were necessary for four patients. Surprisingly, a significant decrease in the patient's height was observed at 1 year (P = 0.03) ( Table 2) .
biochemical markers and hormone assessment. Serum crosslaps was significantly increased (P = 0.004), whereas BAP was not modified. EGFR-MDRD was increased (P < 0.001), while corrected serum calcium (P = 0.01) and CRP (P < 0.01) were decreased. LDH and β2-microglobulin were also decreased, but with borderline significance (P = 0.08 and 0.06, respectively) ( Table 2 ). Serum FSH, LH, free testosterone and total testosterone levels were assessed for 22 men at baseline and for 21 men at 1 year. Serum FSH and LH levels were significantly increased at 1 year (P < 0.0001 for FSH and P = 0.001 for LH), suggesting germ cell dysfunction. Surprisingly, total testosterone was significantly increased at 1 year (P = 0.03), while free testosterone was also increased, although not significantly (Table 2) .
BMD and fractures. During the 1-year study, the mean BMD declined at the lumbar spine (−2.7% ± 3.9%, P < 0.001), femoral neck (−2.2% ± 7.6%, P < 0.01) and total hip (−2.6% ± 4.5%, P < 0.0001) ( Table 2) . Four (12.5%) patients developed new osteoporotic fractures during follow-up. Two patients experienced one symptomatic rib fracture each and two other patients experienced four symptomatic vertebral fractures each accompanied by acute pain and disability.
predictive factors of BMD loss BMD loss at lumbar spine was significantly correlated with eGFR-MDRD (r = 0.41; P = 0.01), whereas BMD loss at femoral neck was correlated with sCTX (r = −0.41; P = 0.02). BMD loss at total hip was correlated with albumin, vitamin D and the patient's weight (r = 0.46; P < 0.01, r = 0.38; P = 0.03 and r = 0.36; P = 0.03, respectively).
Univariate analysis for the factors associated with BMD loss is shown in Table 3 . In multivariate analysis, predictive factors for BMD loss at baseline were (i) at lumbar spine: female gender (P = 0.01), higher LDH level (P = 0.04) and lower creatinine clearance (P = 0.01); (ii) at total hip: lower albumin (P = 0.01), higher corrected serum calcium (P < 0.01), lower AP (P < 0.01) and autologous stem cell transplant (P = 0.03); and (iii) at femoral neck: higher corrected calcium (P = 0.02) and lower BAP (P = 0.01). This prospective study shows for the first time that adult patients with newly diagnosed lymphoma receiving modern chemotherapy regimens experienced, early in the course of the disease, significant BMD loss at the lumbar spine and hip. Four (12.5%) patients developed new osteoporotic fractures during follow-up, although patients at higher risk of future osteoporotic fractures have been initially excluded. Moreover, sCTX was significantly increased at 1 year, reflecting excess bone remodeling and baseline sCTX was correlated with BMD loss at the femoral neck. Numerous predictive factors for BMD loss were identified, reflecting the difficulty of discriminating the main factors involved. Few studies have reported significant bone loss among adult patients with known lymphoma receiving chemotherapy. Holmes et al. [8] showed minor reductions in BMD of the lumbar spine and femoral neck in 29 men treated by combination chemotherapy for Hodgkin's lymphoma compared with age-matched male controls 3.4 years after completion of chemotherapy. Kim et al. [6] showed significant reductions in BMD of the lumbar spine (−11.2%), total hip (−3.6%) and femoral neck (−4.5%) in 20 patients during a 1-year study. Total corticosteroid dose was higher than in our study (mean dose of 7527 ± 5490 mg and mean daily dose >40 mg of prednisone for 6 months). BMD was more markedly decreased, although not significantly, in women at all skeletal sites. Six (30%) of the 20 patients developed new vertebral fractures during follow-up and urinary excretion of Ntelopeptide of type I collagen increased by 21%, corresponding to an increase in bone remodeling as observed in our study. Brown et al. [7] did not observe any detectable effects of chemotherapy on BMD and bone turnover in 115 chemotherapy-treated patients compared with 102 cancer controls, but this cross-sectional study only included male survivors from testicular cancer (n = 64) and lymphoma (n = 51) and the median time since completion of curative treatment was 4.1 years.
The use of chemotherapy was significantly associated with an increased risk of fracture and osteoporosis in elderly patients with NHL in a retrospective cohort of 13 570 patients aged ≥65 years with incident NHL identified from Medicare data with up to 11 years of follow-up [14] . Women and patients treated by radiation therapy were more likely to have osteoporosis and fractures. None of these studies provided data concerning the potential impact of numerous factors on BMD, while our study has shown for the first time that many predictive factors are involved in BMD loss, such as autologous stem cell transplant for BMD loss at total hip. Significant and persistent bone loss at the femoral neck was also demonstrated following stem cell transplant by Gandhi et al. [15] in 44 long-term cancer survivors including patients with HL and NHL. Corticosteroid-induced bone loss mainly induces accelerated bone remodeling, decreasing BMD and increasing the fracture risk as early as 3 months after initiation of oral corticosteroid therapy [16] . However, few studies have examined the use of corticosteroids in patients receiving intermittent short-course chemotherapy, as in the case of treatment of lymphoma. Most NHL regimens, such as CHOP and CVP, include prednisone between 60 and 100 mg orally once a day for 5 days, administered every 3 or 4 weeks for 6-8 courses. De Vries et al. [17] demonstrated that patients who receive several courses of intermittent high-dose glucocorticoids (daily dose >15 mg and cumulative exposure >1 g) have a substantially increased risk of osteoporotic fractures. The present study did not demonstrate any association between corticosteroids and BMD loss 1 year after starting treatment.
Premature ovarian failure has been observed following treatment of lymphoma. The incidence of ovarian dysfunction depends on age and the chemotherapy regimen. Only limited data are available concerning long-term gonadal toxicity in women treated for lymphoma, but the frequency of gonadal dysfunction has been reported to be about 10%-57% [18] [19] [20] . None of the three premenopausal women with lymphoma developed premature ovarian failure during this 1-year study. Several studies have reported increased FSH levels in 80%-90% of men following chemotherapy [21] . Chemotherapy regimens for non-Hodgkin's lymphoma are generally less gonadotoxic than those used for Hodgkin's disease [22, 23] . Men tested in the present study had elevated FSH and LH levels at 1 year, suggesting germ cell dysfunction, but surprisingly, these men also developed increased total testosterone levels, while free testosterone was not modified.
Several limitations of this study should be stressed. First of all, a control group was not used to compare the longitudinal variation of BMD, but the expected changes in BMD as a function of age in women and men have been previously investigated. For women, Berger et al. [24] demonstrated that the annual rate of change was maximal around 50-54 years and equivalent to −0.010 g/cm² at the lumbar spine and −0.007 g/cm² at the proximal femur. For men, the annual rate of change was less than −0.006 g/cm 3 at all sites regardless of age. An interesting review on bone health in adult cancer survivors has recently been published, providing an overview of changes in LS BMD during the first 12 months of various types of cancer therapy [25] . Average BMD loss in the LS was 2.0%-2.5% for androgen-deprivation and aromatase inhibitor therapy. Second, marked heterogeneity was observed between patients in terms of age, gender, tumor factors and treatment regimens, but the purpose of this pilot study was to determine the extent of BMD loss in a cohort of 'real-life' patients, receiving modern chemotherapy with usual concomitant treatment.
Further studies are needed to determine which subjects with lymphoma require BMD testing and to establish clinical practice guidelines. Another concern will be to determine the value of bisphosphonate therapy to prevent bone loss and osteoporotic fractures as reported by two previous studies [6, 26] .
In summary, adult patients with known lymphoma receiving chemotherapy experienced osteoporotic fractures and significant BMD loss in the lumbar spine and proximal femur. Optimizing bone health and preventing osteoporotic fractures are high priorities in these patients.
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